• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Financial Officer Bright Jennifer

    5/20/25 4:40:04 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care
    Get the next $NVNO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Bright Jennifer

    (Last) (First) (Middle)
    C/O ENVVENO MEDICAL CORPORATION,
    70 DOPPLER

    (Street)
    IRVINE CA 92618

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    enVVeno Medical Corp [ NVNO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/19/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options(1) $3.62 05/19/2025 A 350,000 (2) 05/19/2035 Common Stock 350,000 $0 350,000 D
    Explanation of Responses:
    1. The stock option was granted pursuant to the registrant's Amended and Restated 2016 Omnibus Incentive Plan, as amended.
    2. The stock options shall vest quarterly, over a three (3) year period, with a one (1) year cliff, subject to the reporting person's continued service with the Company.
    /s/ Jennifer Bright 05/20/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NVNO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVNO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Bright Jennifer

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      5/20/25 4:40:04 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Bright Jennifer

      3 - enVVeno Medical Corp (0001661053) (Issuer)

      5/20/25 4:35:31 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • Director Duhay Francis bought $249,999 worth of shares (81,433 units at $3.07), increasing direct ownership by 389% to 102,344 units (SEC Form 4)

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      1/3/25 7:00:20 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    Leadership Updates

    Live Leadership Updates

    See more
    • enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

      Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve®PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024IRVINE, CA / ACCESSWIRE / April 9, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Andrew Cormack has been hired as the Company's Chief Commercial Officer. Mr. Cormack, who joined enVVeno Medical on April 8, comes to enVVeno following a career at both start-up and large medical device companies including WallabyPhenox, Medtronic, Covidien,

      4/9/24 8:45:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

      IRVINE, CA / ACCESSWIRE / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at Medtronic.Mr. Belteau joined Medtronic as a field engineer upon graduation from college and has progressed through various clinical operations roles over the course of his tenure there. Most recently he managed his own team of clinical operations professionals and has been directly involved is more than 75 clinical st

      8/16/22 8:05:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    Financials

    Live finance-specific insights

    See more

    $NVNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $NVNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $NVNO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

      85% Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% Median Reduction in Pain (VAS)87% Median Ulcer Area Reduction97% Target Vein Patency RateImprovement in All Patient Reported Quality-of-Life IndicatorsCompany to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st A

      11/20/24 8:30:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

      Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH SymposiumCompany to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 19, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has submitted its application with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell the VenoValve in the United States. Four (4) out of five (5) modules that comprise the VenoValve PMA application

      11/19/24 8:15:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical to Host Conference Call and Webcast on September 21, 2022

      - Conference call with live audio webcast to be held on Wednesday, September 21st at 4:30 PM ETIRVINE, CA / ACCESSWIRE / September 19, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it will host a conference call and webcast on Wednesday, September 21, 2022 at 4:30 PM ET.Interested participants and investors may access the conference call by dialing (877) 407-9708 (domestic) or (201) 689-8259 (international) and referencing conference ID: 13732870. The live webcast will be accessible on the Events page of the Investors section of the enVVeno website, envveno.com, and w

      9/19/22 8:05:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • Director Duhay Francis bought $249,999 worth of shares (81,433 units at $3.07), increasing direct ownership by 389% to 102,344 units (SEC Form 4)

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      1/3/25 7:00:20 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • Director Gray Robert bought $10,290 worth of shares (3,500 units at $2.94), increasing direct ownership by 46% to 11,155 units (SEC Form 4)

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      1/2/25 4:05:22 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • Director Shrivastava Sanjay bought $15,660 worth of shares (5,400 units at $2.90), increasing direct ownership by 139% to 9,288 units (SEC Form 4)

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      12/26/24 4:30:21 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by enVVeno Medical Corporation

      SC 13G/A - enVVeno Medical Corp (0001661053) (Subject)

      11/14/24 4:50:32 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by enVVeno Medical Corporation (Amendment)

      SC 13G/A - enVVeno Medical Corp (0001661053) (Subject)

      2/23/24 4:16:05 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by enVVeno Medical Corporation

      SC 13G - enVVeno Medical Corp (0001661053) (Subject)

      2/14/24 4:51:40 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

      Successful Completion of All Planned Implants in GLP StudyenVVe Delivery System Demonstrates Consistent PerformanceCompany Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful completion of the final wave of implants for shorter-term subjects in its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The successful completion of all planned implants in the GLP study, including both long-t

      12/16/24 8:50:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

      Interviews with participating patients from the VenoValve® U.S. Pivotal TrialWebcast replay from with the presenting Primary InvestigatorsPresentation with data from the VenoValve U.S. Pivotal TrialAccess the Recap Website Here!IRVINE, CA / ACCESSWIRE / November 27, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the launch of a recap website which highlights the Company's participation at the recently held 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium. Materials accessible on the recap website include interviews with two patients and

      11/27/24 8:30:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

      85% Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% Median Reduction in Pain (VAS)87% Median Ulcer Area Reduction97% Target Vein Patency RateImprovement in All Patient Reported Quality-of-Life IndicatorsCompany to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st A

      11/20/24 8:30:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    SEC Filings

    See more
    • enVVeno Medical Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - enVVeno Medical Corp (0001661053) (Filer)

      5/20/25 4:30:22 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by enVVeno Medical Corporation

      10-Q - enVVeno Medical Corp (0001661053) (Filer)

      4/30/25 5:28:15 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

      8-K - enVVeno Medical Corp (0001661053) (Filer)

      4/21/25 4:05:32 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care